SLC5A2 and hydrops fetalis: Analysing the available evidence (EMPA-REG OUTCOME, DECLARE-TIMI 58, VERTIS CV, DAPA-HF, and EMPEROR-Reduced), with the exception of the CANVAS study, SGLT-2 inhibitors do not confer a significantly decreased risk of major adverse cardiovascular events among women.